Trial Profile
Efficacy and Safety of Fixed Dose Combination of Latanoprost 0.005% and Timolol 0.5% Ophthalmic Solution (Sun Pharma Advanced Research Company Ltd.) in Patients with Open Angle Glaucoma or Ocular Hypertension: A Randomized, Open Label, Parallel Group, Active Controlled Study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Latanoprost/timolol (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Sun Pharma Advanced Research Company
- 22 Apr 2015 New trial record